此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Cousin vs. Sibling Donors in Haplo-HSCT

Comparison of Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation From Cousin Donors Versus Sibling Donors in Patients With Hematological Malignancies: A Target Trial Emulation Study

This observational study aims to emulate a hypothetical pragmatic, multicenter, non-blinded clinical trial enrolling adult patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with grafts derived from either cousin or sibiling donors.

The main research question is whether cousin donor-derived haplo-HSCT is associated with inferior clinical outcomes relative to sibling donor-derived haplo-HSCT.

Study participants consist of adult patients diagnosed with hematological malignancies who underwent cousin or sibiling haplo-HSCT between 2017 and 2024, and all eligible recipients will receive regular follow-up assessments.

研究概览

研究类型

观察性的

注册 (估计的)

1000

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Jiangsu
      • Suzhou、Jiangsu、中国、215000
        • The First Affiliated Hospital of Soochow University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

This multicenter, retrospective observational study included adult patients with hematological malignancies undergoing their first haploidentical hematopoietic stem cell transplantation at four clinical centers between 2017 to 2024. Eligible patients were identified through retrospective clinical records and stratified by donor kinship recorded at transplant, classified as either cousin or sibling donor graft recipients.

描述

Inclusion Criteria:

  • Adult patients diagnosed with hematological malignancies, including acute leukemia (AL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and non-Hodgkin lymphoma (NHL)
  • Receipt of first haploidentical hematopoietic stem cell transplantation between 2017 and 2024
  • Documented exact date of transplantation available in medical charts
  • Verifiable donor kinship classified as either cousin or sibiling
  • Complete longitudinal follow-up data accessible for outcome assessment

Exclusion Criteria:

  • Prior receipt of any form of hematopoietic stem cell transplantation
  • An age difference of more than 18 years between the donor and recipient
  • Failure of successful infusion of donor-derived hematopoietic stem cells following conditioning regimen

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Cousin haplo-HSCT
Patients who underwent haploidentical hematopoietic stem cell transplantation with cousin donors. Grouping was based on donor age recorded in retrospective clinical data.
Sibling haplo-HSCT
Patients who underwent haploidentical hematopoietic stem cell transplantation with sibling donors. Grouping was based on donor age recorded in retrospective clinical data.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Overall survival
大体时间:2 years after transplantation
estimated overall survival at 2 year
2 years after transplantation
Graft-versus-host disease-free and relapse-free survival
大体时间:2 years after transplantation
estimated graft-versus-host disease-free and relapse-free survival at 2 year
2 years after transplantation
Cumulative incidence of acute graft-versus-host disease
大体时间:180 days after transplantation
estimated cumulative incidence of acute graft-versus-host disease at 180 day
180 days after transplantation
Cumulative incidence of chronic graft-versus-host disease
大体时间:2 years after transplantation
estimated cumulative incidence of chronic graft-versus-host disease at 2 year
2 years after transplantation

次要结果测量

结果测量
措施说明
大体时间
Cumulative incidence of relapse
大体时间:2 years after transplantation
estimated cumulative incidence of relapse at 2 year
2 years after transplantation
Non-relapse mortality
大体时间:2 years after transplantation
estimated non-relapse mortality at 2 year
2 years after transplantation
Cumulative incidence of grade III-IV acute graft-versus-host disease
大体时间:180 days after transplantation
estimated cumulative incidence of grade III-IV acute graft-versus-host disease at 180 day
180 days after transplantation
Cumulative incidence of extensive chronic graft-versus-host disease
大体时间:2 years after transplantation
estimated cumulative incidence of extensive chronic graft-versus-host disease at 2 year
2 years after transplantation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Yang Xu、The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月1日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2027年10月31日

研究注册日期

首次提交

2026年6月16日

首先提交符合 QC 标准的

2026年6月16日

首次发布 (实际的)

2026年6月23日

研究记录更新

最后更新发布 (实际的)

2026年6月23日

上次提交的符合 QC 标准的更新

2026年6月16日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • TTE2026610

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅